Global Albumin Market Assessment 2017-2021

Human albumin is the most abundant protein present in the blood and comprises almost half of serum protein. The protein is produced in the liver and is responsible for carrying a number of substances through the body such as hormones, cholesterol, fatty acids and bilirubin among others. Albumin is a unique constituent that balances blood volume, can act both as a therapeutic agent for restoration and maintenance of circulating blood volume and to carry therapeutic agents such as pharmaceutical drugs where it acts as an excipient. Albumin is used for treatment of blood loss shock in cases of excessive bleeding, hypoalbuminemia, surgery or burns.

There are three types of albumins used for therapeutics and health that are currently being analyzed for this report by SA-BRC; Bovine & Fetal Bovine Serum (BSA), Recombinant Human Albumin (rHA) and Human Serum Albumin (HSA). The market for albumin is driven by the overall demand from plasma derived proteins, demand from pharmaceutical industry for albumin as an excipient, and as a therapeutic agent in hospitals. Advantages of using HSA as a carrier include are that the substance is native to the body, biodegradable, non-toxic and non-immunogenic, stability over a wide PH range and versatility in binding with different agents. The demand BSA continues to grow steadily stemming from growth of immunodiagnostics, clinical chemistry reagents, cell culture media, protein research, and molecular biology laboratories. Along with BSA, there is also a rising demand for serum albumin from other animal sources such as horses and pigs that is regularly used for research purpose.

Request Free Report Sample@ http://www.sa-brc.com/Global-Albumin-Market-Assessment--Forecast-2017-2021/up74

The report covers the market for these three types of albumin across applications such as drug formulation, drug delivery, vaccines, health& wellness and culture media. The analysis will encompass the market for six geographies of North America, Europe, Asia-Pacific, Latin America, Middle-East & Africa. China is anticipated to be one of the largest markets that imports albumin as the only plasma derived pharmaceutical accounting for 50% of the total plasma-based pharmaceuticals market. Albumin is now being used for unique drug delivery techniques such as microspheres and nanoparticles to deliver NSAIDS and other drugs for oncology.

Key players in this market include Grifols, CSL Behring, Kamada, Sigma Aldrich, Invitria, Albumedix, Merck Millipore, Kaketsuken among several others in a fragmented market. The rHA market is anticipated to grow with the quickest pace in through the forecast period with greatest demand rising from pharmaceutical industry.

Request For TOC@ http://www.sa-brc.com/Global-Albumin-Market-Assessment--Forecast-2017-2021/upcomingdetail74

NOTE: This report is currently under research and will be made available to clients on request.

About Us
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
John Whitmore
Office No. 14,
Hermes Kunj, Mangaldas Road,
Pune, 411001
India
Phone: +91-02041210872
Email: sales@sa-brc.com
Website: www.sa-brc.com

This release was published on openPR.